eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2022
vol. 8
 
Share:
Send email
Share:
abstract:
Original paper

The TM6SF2 variant as a risk factor for hepatocellular carcinoma development in chronic liver disease patients

Gamal Y. S. Raia
1
,
Eman Abdelsameea
1
,
Dalia Hamdy Twfic Taie
1
,
Omar Elshaarawy
1
,
Noha Rabie Bayomy
2
,
Rasha G Mostafa
2
,
Aml Abd Alhamid Alsharnoby
1
,
Karema Abdelhady Diab
1

  1. National Liver Institute, Egypt
  2. Faculty of Medicine, Egypt
Clin Exp HEPATOL 2022; 8, 3: 211-218
DOI: https://doi.org/10.5114/ceh.2022.119265
Online publish date: 2022/09/15
View full text Get citation
 
PlumX metrics:
Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. A non-synonymous single nucleotide polymorphism (SNP) of the transmembrane 6 superfamily member 2 (TM6SF2) gene is associated with non-alcoholic fatty liver disease. SNPs of the TM6SF2 gene play an important role in the pathogenesis of HCC in alcoholic cirrhosis, but there are limited data regarding other possible etiologies. We aimed to evaluate the role of the rs58542926 polymorphism in the development of HCC in Egyptian chronic liver disease (CLD) patients.

Material and methods
A total of 120 participants, including 40 HCC patients, 40 CLD patients, and 40 healthy controls, were selected. Real-time polymerase chain reaction (RT-PCR) was used to detect the TM6SF2 rs58542926 polymorphism.

Results
There were no significant differences among the three studied groups regarding age (p = 0.06) and gender (p = 0.75). Frequencies of the CT, TT, CT + TT genotypes and the T allele were significantly higher in HCC patients than in the CLD and control groups (p < 0.001, p = 0.005, and p < 0.001, respectively). CLD patients with the CT genotype had a significantly increased risk of HCC development (OR = 4.67, 95% CI: 1.67-12.90). Patients with the TT genotype had a significantly increased risk of HCC (OR = 9.33, 95% CI: 1.72-50.61). Moreover, the T allele was correlated with an increased risk of HCC (OR = 5.44, 95% CI: 2.09-14.17) compared to the C allele.

Conclusions
The TM6SF2 rs58542926 genotype is associated with an increased risk of HCC in the Egyptian population.

keywords:

hepatocellular carcinoma, CLD, TM6SF2, polymorphism
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.